Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

	rmaceuticals Inc								
Form 4	2015								
January 13,	_								
FORM	A 4 UNITED	STATES SE				COMMISSION	N OMB	PPROVAL 3235-0287	
Check th	nis box		Washington	, D.C. 20	549		Number:	January 31,	
if no lon subject t Section Form 4 Form 5	16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,					Estimated burden hou response	2005 average urs per	
obligatio may con <i>See</i> Instr 1(b).	ons Section 17((a) of the Publ		ding Con	npany Act	of 1935 or Section			
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> Ashburn Theodore			2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer				
			Dicerna Pharmaceuticals Inc [DRNA]			(Check all applicable)			
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			Director 10% Owner X Officer (give title Other (specify			
	CEUTICALS, IN STREET, BLDC	01/ C., 480	09/2015			below)	below) See Remarks		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
WATERTO	OWN, MA 02472					Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Table I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		e, if Transactio Code ear) (Instr. 8)	nAcquired Disposed (Instr. 3, 4	(A) or of (D) • and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
			Code V		(D) Price				
Reminder: Re	port on a separate line	e for each class o	f securities benef	•		-			
				inform require	ation cont ed to resp	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8 1 2 ()
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Employee Stock Option (Right to Buy)	\$ 18.5	01/09/2015		А	3,333	<u>(1)</u>	01/09/2025	Common Stock	3,333	

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Ashburn Theodore						
C/O DICERNA PHARMACEUTICALS, INC.			See			
480 ARSENAL STREET, BLDG 1, SUITE 120			Remarks			
WATERTOWN, MA 02472						

Signatures

By: /s/ Theodore T. Ashburn	01/13/2015		
<u>**</u>Signature of Reporting Person	Date		

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in 48 monthly installments over the four-year period with a vesting start date of January 9, 2015, subject in each case to the reporting person's continued employment with the issuer through the applicable vesting date.

Remarks:

Senior Vice President, Product Strategy and Operations

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.